A research team at the University at Buffalo analysed the effects of ciclesonide, an inhalable asthma treatment, in COVID patients and found that the treatment group was less likely to visit the emergency room or be hospitalized for reasons related to COVID-19. 

The researchers said that they analysed over 400 COVID-19 patients at 10 centers across the US between June 11, 2020 and November 20, 2020 for their research. The findings of the study, published in JAMA Internal Medicine, clarified the uses of ciclesonide, however, in Covid-19 patients did not clear symptoms more quickly. Ciclesonide also did not help reduce the number of days the patients experience the coronavirus disease symptoms. 

Ciclesonide, though it reduces inflammation and swelling of the airways in the lungs to make breathing easier, does not stop an asthma attack. The inhalation of the drug,  because of its anti-inflammatory property, earlier received attention as a safe and inexpensive treatment method for Covid patients who are not hospitalized.